“Accelerating discovery and achieving breakthroughs more efficiently has been an on-going goal of mine for decades,” said Mr. Fischer-Colbrie was chosen as EY Entrepreneur of the Year, Life Sciences for Northern California and one of three national finalists in 2013. in Finance and Marketing from University of California at Berkeley. Fischer-Colbrie headed Business Development and was CFO of Adeza Biomedical Corporation where he was an inventor on several patents. until its acquisition by Danaher Corporation. Most recently he served for ten years as CEO of Labcyte Inc. Fischer-Colbrie has over 30 years of executive experience in diagnostics, medical devices, therapeutics and laboratory tools and has taken three companies public. He will also sit on the Strateos Board of Directors. The Strateos board is also pleased to announce that Mark Fischer-Colbrie has joined as President and Chief Executive Officer. “We are thrilled to help build a globally impactful and historic company.” “The future of scientific discovery is now happening at the edge where disciplines meet, where advanced biology and high-tech engineering combine, where wet labs, chemistry, 3D imaging and robotic automation technologies operate together to unleash more control and creativity from scientists than ever before possible,” said Strateos Board member and Lux Capital Managing Director Josh Wolfe. But taken together, Strateos can transform the speed, scale, cost, and precision of scientists’ ability to discover new life-saving medicines across multiple steps in the discovery process.” “Each of these companies has enabled multinational pharmaceutical companies to dramatically improve the efficiency of their drug discovery programs. “As a longtime lead investor in both companies, DCVC anticipates the combined entity will be exponentially more impactful,” said Armen Vidian, Strateos Board member and DCVC Operating Partner. In support of the Strateos mission, DCVC (Data Collective) and Lux Capital have invested an additional $16.5M, including support from Dolby Family Ventures, to enable the combined company to expand. Integration of the two companies will be aided by their proximity, with development and production teams operating across California. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development.īoth companies have track records integrating novel artificial intelligence and robotics technologies into the pharmaceutical drug discovery process, and each has realized revenue in-line with the value created by their novel products and services. 3Scan combines automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. SAN FRANCISCO, J(GLOBE NEWSWIRE) - The boards of Transcriptic and 3Scan have unanimously approved an agreement to merge companies to combine their considerable engineering capabilities in developing automated systems for chemistry, biology, and tissue analysis.
0 kommentar(er)
